Specifically, there is a 48% to 76% probability of near-completely eliminating tumor by targeting FOLR1 or MSLN alone, while targeting FOLR1 and MSLN simultaneously was predicted to kill more than 88% of cancer cells based on a cohort of 160 OVs. Here, MSLN is linked to neoplasm.